HIRA criticized over Lipotor’s moderate price reduction

Published: 2009-10-15 06:58:00

Updated: 2009-10-15 06:58:00

The Health Insurance Review and Assessment Service (HIRA)’s recent decision to make a moderate price reduction applied to Lipitor, the world's best-selling medicine made by Pfizer, has invited criticism from a lawmaker.

Rep. Park Eun-soo of the main opposition Democratic Party said that the HI...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK